Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
Derm Research, PLLC
Study ID
NCT03000309
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.

Key Dates

First listed
Dec 22, 2016
Start date
Dec 29, 2016
Status verified
Mar 2019
Primary completion
Apr 30, 2018
Completion
Apr 25, 2018

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Apremilast
    Apremilast, 30 mg. tablets, two times a day for 16 weeks

Primary Outcome Measure

Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 [ Time Frame: Week 16 ]

Locations (1)

FacilityCityStateZIPSite coordinators
DermResearch, PLLCLouisvilleKentucky40217-

Find similar trials in Louisville, KY

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
DermResearch, PLLC· Louisville, KY

Related Studies